title: Glyminox Biosyn.
abstract: Glyminox (Savvy) is a vaginal gel formulation of C31G being developed by Biosyn as a potential contraceptive and for the potential prevention of transmission of sexually transmitted diseases, including HIV infection. In March 2002, glyminox was in phase II/III trials for Chlamydia treatment and as a contraceptive, and in phase II trials for herpes simplex virus shedding.
authors.affiliation: Questor Pharmaceuticals Inc, 3260 Whipple Road, Union City, CA 94587, USA. withmax@comcast.net
authors.forename: Gary W
authors.initials: GW
authors.lastname: Witherell
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic / Q000379:methods / Q000706:statistics & numerical data; D015507:Drugs, Investigational / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D012749:Sexually Transmitted Diseases / Q000188:drug therapy / Q000517:prevention & control*; D013089:Spermatocidal Agents / Q000494:pharmacology / Q000627:therapeutic use; D013678:Technology, Pharmaceutical / Q000379:methods; D014622:Vaginal Creams, Foams, and Jellies / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D015507:Drugs, Investigational; D013089:Spermatocidal Agents; D014622:Vaginal Creams, Foams, and Jellies